X4 Pharmaceuticals Stock Beneish M Score
| XFOR Stock | USD 1.09 0.11 9.17% |
XFOR | Beneish M Score |
At this time, X4 Pharmaceuticals' M Score is unavailable. The earnings manipulation may begin if X4 Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by X4 Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of X4 Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-5.51
Beneish M Score - Unavailable
X4 Pharmaceuticals Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if X4 Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 533.9 K | 562 K |
|
| |||||
| Total Assets | 102.4 M | 147.3 M |
|
| |||||
| Total Current Assets | 83.3 M | 122.1 M |
|
| |||||
| Non Current Assets Total | 19.2 M | 25.2 M |
|
| |||||
| Property Plant Equipment | 1.2 M | 1.3 M |
|
| |||||
| Selling General Administrative | 19.2 M | 32.1 M |
|
| |||||
| Total Current Liabilities | 13.7 M | 22.9 M |
|
| |||||
| Non Current Liabilities Total | 42.1 M | 73.3 M |
|
| |||||
| Short Term Debt | 1.7 M | 1.1 M |
|
| |||||
| Long Term Debt | 27.7 M | 54.6 M |
|
|
X4 Pharmaceuticals Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between X4 Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards X4 Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find X4 Pharmaceuticals' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About X4 Pharmaceuticals Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
X4 Pharmaceuticals Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as X4 Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 2.0M | 917K | 747K | 1.2M | 562K | 533.9K | |
| Total Assets | 160.7M | 122.9M | 117.2M | 155.6M | 147.3M | 102.4M | |
| Total Current Assets | 129.3M | 83.3M | 87.9M | 128.7M | 122.1M | 83.3M | |
| Non Current Assets Total | 31.4M | 39.6M | 29.3M | 26.9M | 25.2M | 19.2M | |
| Property Plant Equipment | 2.4M | 9.2M | 10.2M | 1.1M | 1.3M | 1.2M | |
| Depreciation And Amortization | 7.8M | 351K | 19.5M | (1.0M) | 2.0M | 3.6M | |
| Selling General Administrative | 17.6M | 20.9M | 24.7M | 27.0M | 32.1M | 19.2M | |
| Total Current Liabilities | 9.4M | 11.9M | 14.0M | 22.3M | 22.9M | 13.7M | |
| Non Current Liabilities Total | 22.0M | 38.1M | 38.7M | 59.2M | 73.3M | 42.1M | |
| Net Debt | (103.3M) | (40.3M) | (42.0M) | (83.3M) | (41.2M) | (43.2M) | |
| Short Term Debt | 898K | 786K | 1.9M | 2.5M | 1.1M | 1.7M | |
| Long Term Debt | 20.1M | 33.2M | 33.1M | 32.3M | 54.6M | 27.7M | |
| Operating Income | (51.7M) | (59.9M) | (85.1M) | (87.6M) | (107.5M) | (102.1M) | |
| Total Cash From Operating Activities | (48.1M) | (58.8M) | (70.9M) | (77.1M) | (96.5M) | (91.7M) | |
| Investments | 27.2M | (1.4M) | (615K) | (103K) | (10.1M) | (9.6M) |
About X4 Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze X4 Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of X4 Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of X4 Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards X4 Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, X4 Pharmaceuticals' short interest history, or implied volatility extrapolated from X4 Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether X4 Pharmaceuticals is a strong investment it is important to analyze X4 Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact X4 Pharmaceuticals' future performance. For an informed investment choice regarding XFOR Stock, refer to the following important reports:Check out X4 Pharmaceuticals Piotroski F Score and X4 Pharmaceuticals Altman Z Score analysis. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for XFOR Stock analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (0.44) | Return On Equity (1.62) |
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.